Magazines
Newsletter
Advertise
Search
The Business Magazine - B2B Business News - Site Logo
The Business Magazine - B2B Business News - Site Logo
The Business Magazine July 2024
Read now
PICK YOUR EDITION

Scancell Holdings reports strong progress over six months

The Business Magazine article image for: Scancell Holdings reports strong progress over six months
31 January 2025

Scancell Holdings said it was 'confident' of achieving its 'near-term' clinical milestones as the company posted its interim results for the six months to end-October last year.

The Oxford Science Park-based developer of immunotherapies for treating cancer and infectious disease, told investors the period had seen "strong clinical, development and organisational progress".

A statement from chief executive officer Phillip L'Huillier said: "Our lead cancer vaccine, SCIB1, reported exceptional results in the Phase 2 SCOPE trial for advanced melanoma and is supplemented by good clinical progress with the next generation iSCIB1+ and Modi-1 for Renal Cell Carcinoma and Head & Neck cancer. This leaves multiple clinical milestones in 2025."

L'Huillier, who began as CEO in November last year, added: "The recently announced licensing deal with Genmab for a second anti-glycan antibody and the capital raise of £11.3 million in gross proceeds provide us with a cash runway beyond these milestones into H2 2026."

Key near term milestones for the group include SCIB1 full cohort 1 data in 43 patients reaching 25-week objective response rate (ORR) in mid-2025.

Also eyed is iSCIB1+ full Cohort 3 data in 43 patients reaching 25-week objective response rate (ORR) in the second half of 2025.

The company noted that in December last year it had brought in gross proceeds of £11.3 million via an oversubscribed capital raise with significant participation from both existing and new investors.

Research and development (R&D) costs increased to £8 million (2023: £5.7 million) due to increased manufacturing and clinical costs on the SCOPE trial, the firm said.

Administrative expenses remained consistent at £2.5 million (2023: £2.4 million). The group cash balance as at end-October was £9.1 million, down from £14.8 million at end-April last year.

Scancell reported an operating loss for the six months of £10.5 million, compared to a loss of £8.1 million in the six months to October 31, 2023.

The company is building a pipeline of products using four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies.


Share 

Giles Gwinnett is a writer at The Business Magazine. He has been a journalist for more than 20 years and covered a vast array of topics at a range of media settings - in print and online. After his NCTJ newspaper training, he became a reporter in Hampshire before moving to a news agency in Gloucestershire. In recent years, he has been covering the financial markets along with company news for an investor-focused web portal. His many interests include politics, energy and the environment. He lives in Dorset.

Latest deal ticket

All deals

Events

All events

Related news


Group Titles

Dorset BIZ NewsHampshire BIZ News
crossmenu